newsfilter
← Latest News
GlobeNewswire·

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA)